Summary: bioMérieux's stock price moved lower after the diagnostics group released its H1 2026 results and simultaneously scaled back its medium-term financial roadmap for 2027 and 2028. The company cited a shift in the geopolitical and macroeconomic environment since 2024 as the rationale for trimming targets. The combination of the guidance revision, weaker respiratory test sales and a currency drag weighed on investor sentiment.
Results and guidance revision
Shares in bioMérieux fell 1.9% to trade at 269.35 following publication of the half-year figures and the announcement that the company had lowered its medium-term targets. Management reduced the expected annual organic revenue growth for 2027 and 2028 to a range of 3% 6%, down from the previously communicated roughly 7% compound annual growth rate through 2028. CEBIT growth ambitions for the same period were also trimmed.
What drove H1 performance
Consolidated sales for the first half of 2026 totaled 21,965 million, with organic growth of 0.2%. A pronounced -17% organic decline in BIOFIRE respiratory panel sales - reflecting a notably weaker respiratory season compared with the prior year - was a major factor behind the muted organic top-line performance. Adjusted diluted earnings per share for the half were 1.99, down 4% on an organic basis and 17% on a reported basis.
First-half CEBIT fell 4.9% organically, and management reported a 235 million adverse currency effect that weighed on operating profitability for the period.
Market backdrop and share action
At the same time that bioMérieux reported, the broader French market had been trading on a constructive tone, with the CAC 40 building on recent gains amid easing Middle East tensions and lower oil prices. Despite that favorable macro environment, the company-specific nature of bioMérieux's guidance revision and operating details provided little offset for the stock. The intraday low reached 266.30 and the shares are trading nearer their 52-week low of 265.60 after having fallen substantially from a 52-week high of 128.30.
Context and investor sensitivity
The combination of a reduced multi-year growth roadmap and lower-than-expected operating profitability for the first half was sufficient to pressure the share price. Investors demonstrated sensitivity to any signs of erosion in the company's longer-term earnings trajectory after a year in which the stock has already lost a significant portion of its value relative to its 52-week high.
Note: This article presents the company's reported H1 2026 figures and the revisions to its medium-term targets as disclosed in the company's announcements. No additional forecasts or outside data have been introduced.